JUBLPHARMA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.2
| Stock Code | JUBLPHARMA | Market Cap | 15,888 Cr. | Current Price | 997 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.50 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 944 ₹ | DMA 200 | 982 ₹ | Chg in FII Hold | -0.06 % |
| Chg in DII Hold | 0.40 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 66.0 |
| MACD | 28.5 | Volume | 5,49,627 | Avg Vol 1Wk | 2,27,264 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 45.7 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 30.5 |
📊 Core Financials: Jubilant Pharmova (JUBLPHARMA) shows weak fundamentals. ROCE at 2.91% and ROE at 1.04% reflect poor capital efficiency. Debt-to-equity ratio of 0.02 highlights a virtually debt-free balance sheet. Quarterly PAT of ₹6.6 Cr. improved from a loss of -₹48 Cr., showing recovery, but EPS of ₹1.23 remains very low relative to price levels.
💰 Valuation Indicators: P/E ratio is not meaningful due to weak earnings, but relative to industry PE of 30.5, the stock appears expensive given its low profitability. P/B ratio of ~7.1 (997/141) reflects premium pricing. PEG ratio is unavailable, indicating uncertainty in growth valuation. Dividend yield of 0.50% provides modest income return. Intrinsic value appears lower than current price, requiring caution.
🏢 Business Model & Competitive Advantage: Jubilant Pharmova operates in pharmaceuticals, contract research, and life sciences. Its competitive advantage lies in diversified operations across pharma and CRAMS (Contract Research and Manufacturing Services). However, profitability remains inconsistent, and valuations are stretched compared to peers.
📈 Entry Zone: RSI at 66.0 suggests overbought conditions, while MACD positive indicates bullish momentum. Current price of ₹997 is above DMA levels (50 DMA: ₹944, 200 DMA: ₹982). Entry between ₹930–₹960 may be favorable for long-term investors with high risk tolerance.
⏳ Long-Term Holding Guidance: Jubilant Pharmova benefits from industry demand and diversified business model but faces challenges from weak profitability and expensive valuations. Suitable only for aggressive investors willing to accumulate cautiously near support levels.
Positive
- 🌟 Debt-free balance sheet (Debt-to-equity 0.02)
- 🌟 Recovery from losses (PAT -₹48 Cr. → ₹6.6 Cr.)
- 🌟 Increase in DII holding (+0.40%)
- 🌟 Strong 52-week performance (+45.7%)
Limitation
- ⚠️ Very low ROE (1.04%) and ROCE (2.91%)
- ⚠️ EPS of ₹1.23 is weak
- ⚠️ P/B ratio of ~7.1 indicates premium pricing
- ⚠️ RSI at 66.0 suggests overbought conditions
Company Negative News
- 📉 Decline in FII holding (-0.06%)
- 📉 Weak profitability despite recovery
Company Positive News
- 📈 Recovery from losses in the latest quarter
- 📈 Increase in DII holding (+0.40%)
- 📈 Strong 52-week performance (+45.7%)
Industry
- 🌐 Pharmaceutical and life sciences industry driven by global healthcare demand
- 🌐 Industry P/E at 30.5 reflects moderate valuation
- 🌐 Competition from peers like Sun Pharma, Dr. Reddy’s, and Cipla
Conclusion
✅ Jubilant Pharmova shows weak fundamentals with low returns and expensive valuations but benefits from diversified operations and industry demand. Entry between ₹930–₹960 is suitable only for aggressive investors. Long-term holding requires caution, as profitability remains inconsistent and valuations are stretched compared to peers.
Would you like me to also compare Jubilant Pharmova with peers like Sun Pharma, Dr. Reddy’s, or Cipla to highlight sector positioning?